Tumor GR expression was detected in all 11 evaluable biopsy samples, although GR expression levels were independent of clinical outcome (ie, no significant difference in expression between patients who had OS/PFS above or below the median, or between those with a best response of CR/PR versus stable/progressive/nonevaluable disease). Here, NR3C1 is linked to neoplasm.